Although, it remains unclear whether BDNF changes in PD and AD are a cause or consequence of disease, the first phase-I clinical trial of BDNF gene therapy for cognitive decline in AD commenced last year (Tuszynski, 2021). The gene discussed is BDNF; the disease is Mental deterioration.